Search | TVST | ARVO Journals

Showing 1 – 20 of 28

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

From RCT to real wolrd 8 years experince with anti-VEGF for Type 1 ROP

Domenico Lepore; Lorenzo Orazi; Giulia Amorelli; Danilo Giovanni Giustino; Fernando Molle; Giuseppe M. Albanese

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1723.

ARVO Annual Meeting Abstract June 2023

Ranibizumab for treatment of type 1 ROP: 5 year outcomes of the RAINBOW Trial

Domenico Lepore; Brian W Fleck; Neil Marlow; Alistair Fielder; Andreas Stahl; Han Hao; Annemarie Weisberger; James D Reynolds

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):5125.

ARVO Annual Meeting Abstract June 2023

Validation of a Photographic Retinopathy of Prematurity Severity Score (ROP–SS) and Comparison to the Modified Activity Score (mROP–ActS) in a Retrospective SUNDROP Cohort

Christine Liu Xu; Joel Adu-Brimpong; Henry P. Moshfeghi; Tatiana R. Rosenblatt; Michael Yu; Sean Wang; Moosa Zaidi; Hashem Ghoraba; Suzanne Michalak; Natalia F. Callaway; Edward H. Wood; Andreas Stahl; Domenico Lepore; Darius M Moshfeghi

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3346.

ARVO Annual Meeting Abstract June 2022

Intravitreal aflibercept compared with laser photocoagulation for infants with retinopathy of prematurity: A FIREFLEYE subgroup analysis

Andreas Stahl; Emine Sukgen; Wei-Chi Wu; Domenico Lepore; Noriyuki Azuma; Hidehiko Nakanishi; Jan Mazela; Thomas Schmelter; Sergio Leal; Evra Koefuencue

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3126.

ARVO Annual Meeting Abstract June 2022

Structural and functional ophthalmological follow-up of a preterm population: report at six years of age

Domenico Lepore; Benedetta Caproli; Lorenzo Orazi; giulia Amorelli; Francesca Gallini; Daniela Ricci; Lorenzo Hu; Federico Giannuzzi; Maria Petrianni; Filippo Amore; Giovanni Vento

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):4177 – F0237.

Articles July 2020

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

PDF

Matthew Fidler; Brian W. Fleck; Andreas Stahl; Neil Marlow; James E. Chastain; Jun Li; Domenico Lepore; James D. Reynolds; Michael F. Chiang; Alistair R. Fielder; on behalf of the RAINBOW study group
TAGS: infant, ranibizumab, vascular endothelial growth factor a, infant, premature, retinopathy of prematurity, pharmacodynamics
Trans. Vis. Sci. Tech.. 2020; 9(8):43. https://doi.org/10.1167/tvst.9.8.43

Includes: Supplemental Content

Special Issue July 2020

Convolutional Neural Network Based on Fluorescein Angiography Images for Retinopathy of Prematurity Management

PDF

Domenico Lepore; Marco H. Ji; Monica M. Pagliara; Jacopo Lenkowicz; Nikola D. Capocchiano; Luca Tagliaferri; Luca Boldrini; Vincenzo Valentini; Andrea Damiani; for the FA Team of the Italian ROP Study Group
TAGS: angiogram, convolutional neural networks, fluorescein, fluorescein angiography, retinopathy of prematurity, eye
Trans. Vis. Sci. Tech.. 2020; 9(2):37. https://doi.org/10.1167/tvst.9.2.37

ARVO Annual Meeting Abstract June 2020

Delayed Retinal Vascularization (DV): Initiating event in pathogenesis of Retinopathy of Prematurity (ROP) and potential prognostic indicator for intervention

Tailoi Chan-Ling; Sucheta Kulkarni; Clare Gilbert; Anna Ells; Marco H. Ji; Domenico Lepore

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2778.

ARVO Annual Meeting Abstract July 2019

Oct findings in a ROP population with brain lesions

Lorenzo Orazi; Giulia Maria Amorelli; Daniela Ricci; Fernando Molle; Domenico Lepore

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6523.

ARVO Annual Meeting Abstract July 2019

Optical coherence tomography evaluation of early foveal structural changes after anti-VEGF treatment for type 1 ROP.

Giulia Maria Amorelli; Lorenzo Orazi; Costanza Barresi; Fernando Molle; Domenico Lepore

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6534.

ARVO Annual Meeting Abstract July 2019

Regression patterns of Retinopathy of Prematurity after intravitreal injection of Ranibizumab

Marco H. Ji; Darius Moshfeghi; Ryan A Shields; Zachary Bodnar; Cassie A. Ludwig; Natalia F. Callaway; Theodore Leng; Steven Sanislo; Lorenzo Orazi; Giulia Amorelli; Domenico Lepore

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6538.

ARVO Annual Meeting Abstract July 2018

Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: FA vs OCT-A at 4 years of age

Domenico Lepore; Lorenzo Orazi; Marco H. Ji; Giulia Maria Amorelli; Fernando Molle; Graham E Quinn

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3755.

ARVO Annual Meeting Abstract July 2018

Long term follow-up of laser-treated severe Retinopathy of Prematurity: structural and functional findings

Marco H. Ji; Domenico Lepore; Lorenzo Orazi; Fernando Molle; Giulia Maria Amorelli

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3756.

ARVO Annual Meeting Abstract July 2018

OCT in acute phase Retinopathy of Prematurity

Lorenzo Orazi; Giulia Maria Amorelli; Domenico Lepore; Fernando Molle; Marco H. Ji

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2765.

ARVO Annual Meeting Abstract June 2017

Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: long term effects of foveal dislocation on ocular alignment

Domenico Lepore; Lorenzo Orazi; Filippo Maria Amore; Daniela Ricci; Maria Petrianni; Antonio Baldascino; Marco H Ji; Fernando Molle

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5546.

ARVO Annual Meeting Abstract September 2016

Intravitreal Bevacizumab and Laser Treatment for Type 1 Retinopathy of Prematurity (ROP): Electroretinographic Responses to Full-Field Stimuli

Domenico Lepore; Emily A Swanson; Lorenzo Orazi; Fernando Molle; Antonio Baldascino; James D Akula; Ronald M Hansen; Anne B Fulton

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3599.

ARVO Annual Meeting Abstract April 2014

Vascular Regression in Eyes Treated with Bevacizumab Compared with Eyes Treated with Laser for Type-1 Retinopathy of Prematurity

Giovanni Greaves; Domenico Lepore; Gui-Shuang Ying; Clare Wilson; Jiayan Huang; Karen Karp; Agnieshka Baumritter; Akosua Nti; Yuval Cohen; Graham Quinn

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5390.

ARVO Annual Meeting Abstract April 2014

Effect of sunlight exposure during pregnancy on Retinopathy of Prematurity

Emanuele Tonti; Domenico Lepore; Antonio Baldascino; Lorenzo Orazi; Salvatore Luceri; Fernando Molle; Catholic University of Sacred Heart - Ophthalmology

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5918.

ARVO Annual Meeting Abstract April 2014

A cost effectiveness analysis of cataract surgery

Domenico Lepore; Federico Lucidi; Matteo Ruggeri; Gianfranco Damiani

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6098.

ARVO Annual Meeting Abstract June 2013

FA findings in regressed mild rop

Domenico Lepore; Pierdavide Perrini; Fernando Molle; Lorenzo Orazi; Antonio Baldascino; Rachele DeSantis

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):634.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

From RCT to real wolrd 8 years experince with anti-VEGF for Type 1 ROP

Ranibizumab for treatment of type 1 ROP: 5 year outcomes of the RAINBOW Trial

Validation of a Photographic Retinopathy of Prematurity Severity Score (ROP–SS) and Comparison to the Modified Activity Score (mROP–ActS) in a Retrospective SUNDROP Cohort

Intravitreal aflibercept compared with laser photocoagulation for infants with retinopathy of prematurity: A FIREFLEYE subgroup analysis

Structural and functional ophthalmological follow-up of a preterm population: report at six years of age

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

Convolutional Neural Network Based on Fluorescein Angiography Images for Retinopathy of Prematurity Management

Delayed Retinal Vascularization (DV): Initiating event in pathogenesis of Retinopathy of Prematurity (ROP) and potential prognostic indicator for intervention

Oct findings in a ROP population with brain lesions

Optical coherence tomography evaluation of early foveal structural changes after anti-VEGF treatment for type 1 ROP.

Regression patterns of Retinopathy of Prematurity after intravitreal injection of Ranibizumab

Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: FA vs OCT-A at 4 years of age

Long term follow-up of laser-treated severe Retinopathy of Prematurity: structural and functional findings

OCT in acute phase Retinopathy of Prematurity

Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: long term effects of foveal dislocation on ocular alignment

Intravitreal Bevacizumab and Laser Treatment for Type 1 Retinopathy of Prematurity (ROP): Electroretinographic Responses to Full-Field Stimuli

Vascular Regression in Eyes Treated with Bevacizumab Compared with Eyes Treated with Laser for Type-1 Retinopathy of Prematurity

Effect of sunlight exposure during pregnancy on Retinopathy of Prematurity

A cost effectiveness analysis of cataract surgery

FA findings in regressed mild rop

To View More...

You must be signed into an individual account to use this feature.